Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter

Completed

Conditions studied: Pancreatic Neoplasms

In brief

This is an observational study to assess patient survival and clinical outcomes after the RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.

Key facts

Study ID

NCT02591082

Run by

RenovoRx

People needed

25

Starts

2015-12-01

Expected to finish

2021-02-26

Last updated by the study team

2021-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age
• Diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma confirmed by histology or cytology
• Without current myelotoxicity and with sufficient health status to undergo a catheterization procedure
• Willing to provide informed consent and comply with the required follow-up.

You may not qualify if…

• Have received prior chemotherapy and/or radiation therapy within 14 days prior to the first intra-arterial treatment.
• Currently participating in another active drug or device study or registry protocol that would interfere with this study.
• Vulnerable populations: prisoners, pregnant or breastfeeding females.

Where it is running

• Good Samaritan Hospital — San Jose, California, United States
• Fawcett Memorial Hospital — Port Charlotte, Florida, United States
• Florida Hospital — Tampa, Florida, United States
• Montefiore Hospital — The Bronx, New York, United States
• East Carolina University — Greenville, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.